Open-Label Tolvaptan Study in Subjects With ADPKD (TEMPO 4/4)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT01214421
First received: September 26, 2010
Last updated: February 28, 2014
Last verified: February 2014
  Purpose

To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from baseline (from trial 156-04-251) in total kidney volume (TKV) and renal function.


Condition Intervention Phase
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Drug: Tolvaptan
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:
  • Percent Change in Total Kidney Volume (TKV) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    For subjects continuing from protocol 156-04-251: change from 251 baseline TKV at month 24 of 156-08-271 comparing those previously treated with tolvaptan to those previously treated with placebo


Secondary Outcome Measures:
  • Change in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    For subjects randomized to tolvaptan and placebo in 156-04-251 and enrolled and treated in 156-08-271 as early treated and delayed treatment groups: change from 251 baseline eGFR at month 24 of 156-08-271

  • Slope of Total Kidney Value (TKV) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    For subjects randomized to tolvaptan and placebo in 156-04-251 and enrolled and treated in 156-08-271 as early treated and delayed treatment groups

  • Slope of eGFR (CKD-EPI) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    For subjects randomized to tolvaptan and placebo in 156-04-251 and enrolled and treated in 156-08-271 as early treated and delayed treatment groups


Estimated Enrollment: 1500
Study Start Date: May 2010
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 251 Prior Tolvaptan
Patients enrolling from protocol 156-04-251 in the tolvaptan-treated group
Drug: Tolvaptan
Daily split-dose of tolvaptan titrated to the maximally tolerated dose. Starting daily tolvaptan dose of 45mg/15mg titrated to 60mg/30mg, then 90mg/30mg based on tolerability.
Other Names:
  • OPC-41061
  • OPC-156
Experimental: 251 Prior Placebo
Patients enrolling from protocol 156-04-251 in the placebo-treated group
Drug: Tolvaptan
Daily split-dose of tolvaptan titrated to the maximally tolerated dose. Starting daily tolvaptan dose of 45mg/15mg titrated to 60mg/30mg, then 90mg/30mg based on tolerability.
Other Names:
  • OPC-41061
  • OPC-156
Experimental: Other Prior Study
Patients enrolling from prior tolvaptan studies other than protocol 156-04-251
Drug: Tolvaptan
Daily split-dose of tolvaptan titrated to the maximally tolerated dose. Starting daily tolvaptan dose of 45mg/15mg titrated to 60mg/30mg, then 90mg/30mg based on tolerability.
Other Names:
  • OPC-41061
  • OPC-156

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects who have successfully completed a Phase 1, 2, or 3 tolvaptan ADPKD or renal impairment trial, with a confirmed diagnosis of ADPKD

Exclusion Criteria:

  • Subjects unable to provide written informed consent
  • Subjects (men or women) who will not adhere to the reproductive precautions as outlined in the Informed Consent Form
  • Subjects (women only) with a positive urine pregnancy test
  • Subjects who are pregnant or breast-feeding
  • Subjects unable to take oral medications
  • Subjects who have allergic reactions to tolvaptan or chemically related structures such as benzazepines (benzazepril, conivaptan, fenoldopam mesylate or mirtazapine)
  • Subjects who have disorders in thirst recognition or an inability to access fluids
  • Subjects with critical electrolyte imbalances, as determined by the investigator
  • Subjects with or at risk of significant hypovolemia, as determined by investigator
  • Subjects with anemia, as determined by investigator
  • Subjects with a history of substance abuse (within the last 3 years)
  • Subjects taking other experimental (ie, non-marketed) therapies or current participation in another clinical drug or device trial; current participation in the off-drug follow-up period of another ADPKD trial with tolvaptan is permitted

Efficacy Analysis Exclusion Criteria:

  • Subjects unable to complete MRI assessments(eg, subjects with ferro-magnetic prostheses, aneurysm clips, severe claustrophobia)
  • Subjects who have taken a vasopressin antagonist (outside of previous participation in a tolvaptan trial)
  • Subjects unable to comply with anti-hypertensive or other important medical therapy
  • Subjects with advanced diabetes
  • Subjects taking medications or having an illness that could confound endpoint assessments (including taking approved therapies for the purpose of affecting PKD cysts)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01214421

  Hide Study Locations
Locations
United States, Alabama
Otsuka Investigational Site
Mobile, Alabama, United States, 36617
United States, Arizona
Otsuka Investigational Site
Peoria, Arizona, United States, 85381
Otsuka Investigational Site
Tempe, Arizona, United States, 85284
United States, California
Otsuka Investigational Site
Los Angeles, California, United States, 90025
Otsuka Investigational Site
Palo Alto, California, United States, 94304
Otsuka Investigational Site
San Diego, California, United States, 92108
United States, Colorado
Otsuka Investigational Site
Aurora, Colorado, United States, 80045
United States, Connecticut
Otsuka Investigational Site
New Haven, Connecticut, United States, 06510
United States, Florida
Otsuka Investigational Site
Jacksonville, Florida, United States, 32216
Otsuka Investigational Site
Port Charlotte, Florida, United States, 33952
United States, Georgia
Otsuka Investigational Site
Atlanta, Georgia, United States, 30322
Otsuka Investigational Site
Augusta, Georgia, United States, 30909
United States, Illinois
Otsuka Investigational Site
Chicago, Illinois, United States, 60611
United States, Kansas
Otsuka Investigational Site
Kansas City, Kansas, United States, 66160
United States, Louisiana
Otsuka Investigational Site
Baton Rouge, Louisiana, United States, 70808
United States, Maryland
Otsuka Investigational Site
Baltimore, Maryland, United States, 21205
Otsuka Investigational Site
Rockville, Maryland, United States, 20850
United States, Massachusetts
Otsuka Investigational Site
Boston, Massachusetts, United States, 02111
United States, Michigan
Otsuka Investigational Site
Detroit, Michigan, United States, 48236
United States, Minnesota
Otsuka Investigational Site
Minneapolis, Minnesota, United States, 55404
Otsuka Investigational Site
Rochester, Minnesota, United States, 55905
United States, New Jersey
Otsuka Investigational Site
Voorhees, New Jersey, United States, 08043
United States, New York
Otsuka Investigational Site
Buffalo, New York, United States, 14215
Otsuka Investigational Site
Hawthorne, New York, United States, 10532
Otsuka Investigational Site
New York, New York, United States, 10021
Otsuka Investigational Site
New York, New York, United States, 10032
United States, North Carolina
Otsuka Investigational Site
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Otsuka Investigational Site
Cincinnati, Ohio, United States, 45246
Otsuka Investigational Site
Cleveland, Ohio, United States, 44106
United States, Oregon
Otsuka Investigational Site
Portland, Oregon, United States, 97210
United States, Pennsylvania
Otsuka Investigational Site
Bethleham, Pennsylvania, United States, 18017
Otsuka Investigational Site
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Otsuka Investigational Site
Anderson, South Carolina, United States, 29621
United States, Tennessee
Otsuka Investigational Site
Nashville, Tennessee, United States, 37205
Otsuka Investigational Site
Nashville, Tennessee, United States, 37232
United States, Texas
Otsuka Investigational Site
Arlington, Texas, United States, 76015
Otsuka Investigational Site
McAllen, Texas, United States, 78503
United States, Virginia
Otsuka Investigational Site
Charlottesville, Virginia, United States, 22908
Argentina
Otsuka Investigational Site
C.a.b.a., Buenos Aires, Argentina, C1429BWN
Otsuka Investigational Site
Pilar, Buenos Aires, Argentina, B1629ODT
Otsuka Investigational Site
Buenos Aires, Argentina, C1425APQ
Otsuka Investigational Site
Cordoba, Argentina, X5000IUP
Otsuka Investigational Site
Cordoba, Argentina, X5016KEH
Australia, New South Wales
Otsuka Investigational Site
St. Leonards, New South Wales, Australia, 2065
Otsuka Investigational Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Otsuka Investigational Site
Woollongabba, Queensland, Australia, 4102
Australia, South Australia
Otsuka Investigational Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Otsuka Investigational Site
Parkville, Victoria, Australia, 3050
Otsuka Investigational Site
Richmond, Victoria, Australia, 3121
Australia, Western Australia
Otsuka Investigational Site
Perth, Western Australia, Australia, 6000
Belgium
Otsuka Investigational Site
Brussels, Belgium, 1200
Otsuka Investigational Site
Brussels, Belgium, 1090
Otsuka Investigational Site
Gent, Belgium, 9000
Canada, Nova Scotia
Otsuka Investigational Site
Halifax, Nova Scotia, Canada, B3H 1V8
Canada, Quebec
Otsuka Investigational Site
Montreal, Quebec, Canada, H3A1A1
Otsuka Investigational Site
Montreal, Quebec, Canada, H4J1C5
France
Otsuka Investigational Site
Bordeaux, France, 33076
Otsuka Investigational Site
Caen Cedex, France, 14033
Otsuka Investigational Site
Lyon Cedex 3, France, 69437
Otsuka Investigational Site
Paris, France, 75018
Otsuka Investigational Site
Reims Cedex, France, 51092
Otsuka Investigational Site
Saint-Etienne Cedex 2, France, 42055
Otsuka Investigational Site
Toulouse Cedex 09, France, 31059
Germany
Otsuka Investigational Site
Dresden, Germany, 01307
Otsuka Investigational Site
Dusseldorf, Germany, 40210
Otsuka Investigational Site
Essen, Germany, 45122
Otsuka Investigational Site
Heidelberg, Germany, 69120
Otsuka Investigational Site
Nurnberg, Germany, 90471
Italy
Otsuka Investigational Site
Bergamo, Italy, 24127
Otsuka Investigational Site
Milano, Italy, 20132
Otsuka Investigational Site
Modena, Italy, 41100
Otsuka Investigational Site
Napoli, Italy, 80131
Otsuka Investigational Site
Pavia, Italy, 27100
Netherlands
Otsuka Investigational Site
Amsterdam, Netherlands, 1081 HV
Otsuka Investigational Site
Groningen, Netherlands, 9713 GZ
Poland
Otsuka Investigational Site
Ciechanów, Poland, 06-400
Otsuka Investigational Site
Gdansk, Poland, 80-211
Otsuka Investigational Site
Krakow, Poland, 31-501
Otsuka Investigational Site
Lodz, Poland, 90-153
Otsuka Investigational Site
Lublin, Poland, 20-954
Otsuka Investigational Site
Szczecin, Poland, 70-111
Otsuka Investigational Site
Warszawa, Poland, 04-749
Otsuka Investigational Site
Wroclaw, Poland, 50-417
Romania
Otsuka Investigational Site
Bucuresti, Romania, 022328
Otsuka Investigational Site
Bucuresti, Romania, 010731
Otsuka Investigational Site
Iasi, Romania, 700504
Russian Federation
Otsuka Investigational Site
Kemerovo, Russian Federation, 650029
Otsuka Investigational Site
St. Petersburg, Russian Federation, 191104
Otsuka Investigational Site
Tomsk, Russian Federation, 634063
United Kingdom
Otsuka Investigational Site
Belfast, United Kingdom, BT9 7AB
Otsuka Investigational Site
Birmingham, United Kingdom, B15 2TH
Otsuka Investigational Site
Brighton, United Kingdom, BN2 5BE
Otsuka Investigational Site
Coventry, United Kingdom, CV2 2DX
Otsuka Investigational Site
Edinburgh, United Kingdom, EH16 4SA
Otsuka Investigational Site
Inverness, United Kingdom, IV2 3UJ
Otsuka Investigational Site
London, United Kingdom, SE5 9RS
Otsuka Investigational Site
London, United Kingdom, SW17 0QT
Otsuka Investigational Site
London, United Kingdom, NW3 2QG
Otsuka Investigational Site
Swansea, United Kingdom, SA6 6NL
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Investigators
Study Director: Frank Czerwiec, MD, PhD Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

No publications provided by Otsuka Pharmaceutical Development & Commercialization, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT01214421     History of Changes
Other Study ID Numbers: 156-08-271, 2010-018401-10
Study First Received: September 26, 2010
Last Updated: February 28, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Argentina: Ministry of Health
Australia: Human Research Ethics Committee
United Kingdom: Medicines and Healthcare Products Regulatory Agency
France: National Consultative Ethics Committee for Health and Life Sciences
Germany: Federal Institute for Drugs and Medical Devices
Italy: Ethics Committee
Belgium: Ethics Committee
Netherlands: Independent Ethics Committee
Poland: Ethics Committee
Romania: Ethics Committee
Russia: Ethics Committee

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Kidney Disease
ADPKD
Autosomal Dominant Polycystic Kidney Disease
Adult Polycystic Kidney Disease

Additional relevant MeSH terms:
Kidney Diseases
Polycystic Kidney Diseases
Multicystic Dysplastic Kidney
Polycystic Kidney, Autosomal Dominant
Urologic Diseases
Kidney Diseases, Cystic
Urogenital Abnormalities
Congenital Abnormalities

ClinicalTrials.gov processed this record on August 20, 2014